M. Teva and G. Janssen-cilag, PS (advisory boards for Celgene and Teva; honoraria from Spectrum Pharmaceuticals and Pierre Fabre Oncology; travel grants from Hospira, Celgene and Teva), MS (speaker's bureau and advisory boards for CTI BioPharma and Servier; research support, consultant, speaker's bureau and advisory boards for Menarini; speaker's bureau for Roche and Takeda), RS (research support from Celgene, Novartis and Teva; honoraria from Celgene, Novartis and Teva; scientific advisory board for Celgene EZ (advisory honoraria and/or support for investigator-initiated studies for the institution from Celgene, boards from Celgene; travel grants and honoraria for company symposia from Riemser Pharma and CTI Life Sciences) ASB (consultancy fees from Takeda), MT (consultancy for Roche JW (advisory boards for Roche UW (speaker honoraria from Amgen, Novartis, Roche and Chugai) All remaining authors have declared no conflicts of interest. references 1. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients, pp.139-144, 2001.

M. Dreyling, M. Ghielmini, and R. Marcus, Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, issue.suppl 3, pp.76-82, 2014.
DOI : 10.1093/annonc/mdu200
URL : http://annonc.oxfordjournals.org/cgi/content/short/22/suppl_6/vi59

D. Eichenauer, A. Engert, and M. André, Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, issue.suppl 3, pp.70-75, 2014.
DOI : 10.1093/annonc/mdu181

H. Tilly, M. Gomes-da-silva, and U. Vitolo, Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, issue.suppl 5, pp.116-125, 2015.
DOI : 10.1093/annonc/mdv304
URL : http://annonc.oxfordjournals.org/cgi/content/short/23/suppl_7/vii78

B. Eichhorst, T. Robak, and E. Montserrat, Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, issue.suppl 5, pp.78-84, 2015.
DOI : 10.1093/annonc/mdv303
URL : http://annonc.oxfordjournals.org/cgi/content/short/21/suppl_5/v162

M. Dreyling, C. Geisler, and H. O. , Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.25, issue.suppl 3, pp.83-92, 2014.
DOI : 10.1093/annonc/mdu264

S. Barrington, N. Mikhaeel, and L. Kostakoglu, Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group, Journal of Clinical Oncology, vol.32, issue.27, pp.3048-3058, 2014.
DOI : 10.1200/JCO.2013.53.5229

A. Gallamini, M. Hutchings, and L. Rigacci, F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study, Journal of Clinical Oncology, vol.25, issue.24, pp.3746-3752, 2007.
DOI : 10.1200/JCO.2007.11.6525

J. Smeltzer, A. Cashen, and Q. Zhang, Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation, Biology of Blood and Marrow Transplantation, vol.17, issue.11, pp.1646-1652, 2011.
DOI : 10.1016/j.bbmt.2011.04.011

A. Moskowitz, J. Yahalom, and T. Kewalramani, Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma, Blood, vol.116, issue.23, pp.4934-4937, 2010.
DOI : 10.1182/blood-2010-05-282756

V. Safar, J. Dupuis, and E. Itti, F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab, Journal of Clinical Oncology, vol.30, issue.2, pp.184-190, 2012.
DOI : 10.1200/JCO.2011.38.2648

M. Hutchings, A. Loft, and M. Hansen, FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma, Blood, vol.107, issue.1, pp.52-59, 2006.
DOI : 10.1182/blood-2005-06-2252

C. Moskowitz, H. Schöder, and J. Teruya-feldstein, Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma, Journal of Clinical Oncology, vol.28, issue.11, pp.1896-1903, 2010.
DOI : 10.1200/JCO.2009.26.5942

M. Meignan, A. Gallamini, C. Haioun, and A. Polliack, Report on the Second International Workshop on interim positron emission tomography in lymphoma, Leuk Lymphoma, vol.51, pp.8-9, 2010.

A. Gallamini, S. Barrington, and A. Biggi, The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale, Haematologica, vol.99, issue.6, pp.1107-1113, 2014.
DOI : 10.3324/haematol.2013.103218

E. Itti, M. Meignan, and A. Berriolo-riedinger, An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ??SUVmax, European Journal of Nuclear Medicine and Molecular Imaging, vol.119, issue.Suppl 1, pp.1312-1320, 2013.
DOI : 10.1007/s00259-013-2435-6

A. Biggi, A. Gallamini, and S. Chauvie, International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers, Journal of Nuclear Medicine, vol.54, issue.5, pp.683-690, 2013.
DOI : 10.2967/jnumed.112.110890

R. Casasnovas, M. Meignan, and A. Berriolo-riedinger, SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma, Blood, vol.118, issue.1, pp.37-43, 2011.
DOI : 10.1182/blood-2010-12-327767

M. Meignan, A. Gallamini, and C. Haioun, Report on the 5th International Workshop on Positron Emission Tomography in Lymphoma, Leuk Lymphoma, vol.19, issue.56, pp.1229-1232, 2014.

P. Johnson, M. Federico, and A. Fossa, Response-adapted therapy based on interim FDG-PET scans in advanced Hodgkin lymphoma: first analysis of the safety of de-escalation and efficacy of escalation in the international RATHL study (CRUK/07/033), Hematol Oncol, vol.33, issue.1, p.102, 2015.

J. Raemaekers, Early FDG-PET adapted treatment improved the outcome of early FDG-PET positive patients with stages I/II Hodgkin lymphoma (HL): final results of the randomized Intergroup EORTC/LYSA/FIL H10 trial, 13th International Conference on Malignant Lymphoma, 2015.

P. Zinzani, A. Broccoli, and D. Gioia, Interim Positron Emission Tomography Response???Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study, Journal of Clinical Oncology, vol.34, issue.12, pp.1376-1385, 2016.
DOI : 10.1200/JCO.2015.63.0699

M. Hutchings, L. Kostakoglu, and J. Zaucha, In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma, Journal of Clinical Oncology, vol.32, issue.25, pp.2705-2711, 2014.
DOI : 10.1200/JCO.2013.53.2838

M. Hutchings, N. Mikhaeel, and P. Fields, Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma, Annals of Oncology, vol.16, issue.7, pp.1160-1168, 2005.
DOI : 10.1093/annonc/mdi200

J. Radford, T. Illidge, and N. Counsell, Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin???s Lymphoma, New England Journal of Medicine, vol.372, issue.17, pp.1598-1607, 2015.
DOI : 10.1056/NEJMoa1408648

N. Mikhaeel, M. Hutchings, and P. Fields, FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma, Annals of Oncology, vol.16, issue.9, pp.1514-1523, 2005.
DOI : 10.1093/annonc/mdi272

C. Haioun, E. Itti, and A. Rahmouni, [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome, Blood, vol.106, issue.4, pp.1376-1381, 2005.
DOI : 10.1182/blood-2005-01-0272

A. Cashen, F. Dehdashti, and J. Luo, 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation, Journal of Nuclear Medicine, vol.52, issue.3, pp.386-392, 2011.
DOI : 10.2967/jnumed.110.082586

E. Itti, C. Lin, and J. Dupuis, Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy, Journal of Nuclear Medicine, vol.50, issue.4, pp.527-533, 2009.
DOI : 10.2967/jnumed.108.057703

H. Mocikova, R. Pytlik, and J. Markova, Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma, Leukemia & Lymphoma, vol.91, issue.9, pp.1668-1674, 2011.
DOI : 10.1200/JCO.2007.15.5887

A. Becherer, M. Mitterbauer, and U. Jaeger, Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation, Leukemia, vol.16, issue.2, pp.260-267, 2002.
DOI : 10.1038/sj.leu.2402342

T. Terasawa, I. Dahabreh, and T. Nihashi, Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Response Assessment Before High-Dose Chemotherapy for Lymphoma: A Systematic Review and Meta-Analysis, The Oncologist, vol.15, issue.7, pp.750-759, 2010.
DOI : 10.1634/theoncologist.2010-0054

M. Dickinson, R. Hoyt, and A. Roberts, Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy, British Journal of Haematology, vol.19, pp.39-45, 2010.
DOI : 10.1111/j.1365-2141.2010.08162.x

U. Cremerius, U. Fabry, and J. Wildberger, Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin???s lymphoma, Bone Marrow Transplantation, vol.30, issue.2, pp.103-111, 2002.
DOI : 10.1038/sj.bmt.1703607

K. Spaepen, S. Stroobants, and P. Dupont, Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation, Blood, vol.102, issue.1, pp.53-59, 2003.
DOI : 10.1182/blood-2002-12-3842

J. Filmont, J. Czernin, and C. Yap, Value of F-18 Fluorodeoxyglucose Positron Emission Tomography for Predicting the Clinical Outcome of Patients With Aggressive Lymphoma Prior to and After Autologous Stem-Cell Transplantation*, Chest, vol.124, issue.2, pp.608-613, 2003.
DOI : 10.1378/chest.124.2.608

J. Raemaekers, M. André, and M. Federico, Omitting Radiotherapy in Early Positron Emission Tomography???Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial, Journal of Clinical Oncology, vol.32, issue.12, pp.1188-1194, 2014.
DOI : 10.1200/JCO.2013.51.9298

A. Gallamini, A. Rossi, and C. Patti, Interim PET-adapted chemotherapy in advanced Hodgkin lymphoma (HL) Results of the second interim analysis of the Italian GITIL/FIL DH0607 trial, Hematol Oncol, vol.33, pp.163-164, 2015.

P. Johnson, M. Federico, and A. Kirkwood, Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin???s Lymphoma, New England Journal of Medicine, vol.374, issue.25, pp.2419-2429, 2016.
DOI : 10.1056/NEJMoa1510093
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961236

O. Press, H. Li, and H. Schöder, US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose???Positron Emission Tomography Imaging: Southwest Oncology Group S0816, Journal of Clinical Oncology, vol.34, issue.17, pp.2020-2027, 2016.
DOI : 10.1200/JCO.2015.63.1119

T. Soussi, Gene Network in a Postgenomic Era, Human Mutation, vol.2, issue.6, pp.641-642, 2014.
DOI : 10.1002/humu.22562

T. Soussi and K. Wiman, TP53: an oncogene in disguise, Cell Death and Differentiation, vol.6, issue.8, pp.1239-1249, 2015.
DOI : 10.1016/j.ccr.2014.01.021
URL : https://hal.archives-ouvertes.fr/hal-01188060

T. Zenz, D. Vollmer, and M. Trbusek, TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations, Leukemia, vol.112, issue.12, pp.2072-2079, 2010.
DOI : 10.1002/gcc.2870040102

R. Foà, D. Giudice, I. Guarini, and A. , Clinical implications of the molecular genetics of chronic lymphocytic leukemia, Haematologica, vol.98, issue.5, pp.675-685, 2013.
DOI : 10.3324/haematol.2012.069369

M. Hallek, B. Cheson, and D. Catovsky, Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, issue.12, pp.5446-5456, 2008.
DOI : 10.1182/blood-2007-06-093906

D. Oscier, C. Dearden, and E. Eren, Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia, British Journal of Haematology, vol.119, pp.541-564, 2012.
DOI : 10.1111/bjh.12067

S. Pospisilova, D. Gonzalez, and J. Malcikova, ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia, Leukemia, vol.114, issue.7, pp.1458-1461, 2012.
DOI : 10.1200/JCO.2006.08.3089

S. Stilgenbauer, Prognostic markers and standard management of chronic lymphocytic leukemia, Hematology, vol.2015, issue.1, pp.368-377, 2015.
DOI : 10.1182/asheducation-2015.1.368

H. Döhner, S. Stilgenbauer, and A. Benner, Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.343, issue.26, pp.1910-1916, 2000.
DOI : 10.1056/NEJM200012283432602

D. Catovsky, S. Richards, and E. Matutes, Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial, The Lancet, vol.370, issue.9583, pp.230-239, 2007.
DOI : 10.1016/S0140-6736(07)61125-8

M. Hallek, K. Fischer, and G. Fingerle-rowson, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial, The Lancet, vol.376, issue.9747, pp.1164-1174, 2010.
DOI : 10.1016/S0140-6736(10)61381-5

T. Zenz, B. Eichhorst, and R. Busch, Mutation and Survival in Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.28, issue.29, pp.4473-4479, 2010.
DOI : 10.1200/JCO.2009.27.8762

D. Gonzalez, P. Martinez, and R. Wade, Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial, Journal of Clinical Oncology, vol.29, issue.16, pp.2223-2229, 2011.
DOI : 10.1200/JCO.2010.32.0838

D. Rossi, H. Khiabanian, and V. Spina, Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia, Blood, vol.123, issue.14, pp.2139-2147, 2014.
DOI : 10.1182/blood-2013-11-539726

S. Stilgenbauer, A. Schnaiter, and P. Paschka, Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial, Blood, vol.123, issue.21, pp.3247-3254, 2014.
DOI : 10.1182/blood-2014-01-546150

O. Shea, D. O-'riain, C. Taylor, and C. , The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival, Blood, vol.112, issue.8, pp.3126-3129, 2008.
DOI : 10.1182/blood-2008-05-154013

Z. Xu-monette, L. Wu, and C. Visco, Mutational Profile and Prognostic Significance of TP53 in Diffuse Large B-cell Lymphoma Patients Treated with Rituximab-CHOP: A Report From an International DLBCL Rituximab-CHOP Consortium Program Study, Clinical Lymphoma Myeloma and Leukemia, vol.13, pp.3986-3996, 2012.
DOI : 10.1016/j.clml.2013.07.094

S. Pospisilova, L. Sutton, and J. Malcikova, Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?, Haematologica, vol.101, issue.3, pp.263-265, 2016.
DOI : 10.3324/haematol.2015.139246

J. Byrd, J. Brown, O. Brien, and S. , Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia, New England Journal of Medicine, vol.371, issue.3, pp.213-223, 2014.
DOI : 10.1056/NEJMoa1400376
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4134521

P. Dreger, J. Schetelig, and N. Andersen, Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?, Blood, vol.124, issue.26, pp.3841-3849, 2014.
DOI : 10.1182/blood-2014-07-586826

R. Furman, J. Sharman, and S. Coutre, Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.370, issue.11, pp.997-1007, 2014.
DOI : 10.1056/NEJMoa1315226
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365

J. Burger, A. Tedeschi, and P. Barr, Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.373, issue.25, pp.2425-2437, 2015.
DOI : 10.1056/NEJMoa1509388
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722809

H. Stein, R. Warnke, and W. Chan, Diffuse large B-cell lymphoma, not otherwise specified, WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues, pp.233-237, 2008.

A. Alizadeh, M. Eisen, and R. Davis, Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Nature, vol.303, issue.6769, pp.503-511, 2000.
DOI : 10.1038/35000501

S. Monti, K. Savage, and J. Kutok, Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response, Blood, vol.105, issue.5, pp.1851-1861, 2005.
DOI : 10.1182/blood-2004-07-2947

M. Shipp, K. Ross, and P. Tamayo, Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning, Nature Medicine, vol.8, issue.1, pp.68-74, 2002.
DOI : 10.1038/nm0102-68

G. Lenz, G. Wright, and S. Dave, Stromal Gene Signatures in Large-B-Cell Lymphomas, New England Journal of Medicine, vol.359, issue.22, pp.2313-2323, 2008.
DOI : 10.1056/NEJMoa0802885

A. Rosenwald, G. Wright, and W. Chan, The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.25, pp.1937-1947, 2002.
DOI : 10.1056/NEJMoa012914

G. Wright, B. Tan, and A. Rosenwald, A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma, Proceedings of the National Academy of Sciences, vol.100, issue.17, pp.9991-9996, 2003.
DOI : 10.1073/pnas.1732008100

L. Colomo, A. López-guillermo, and M. Perales, Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma, Blood, vol.101, issue.1, pp.78-84, 2003.
DOI : 10.1182/blood-2002-04-1286

C. Hans, D. Weisenburger, and T. Greiner, Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, issue.1, pp.275-282, 2004.
DOI : 10.1182/blood-2003-05-1545

J. Muris, C. Meijer, and W. Vos, Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma, The Journal of Pathology, vol.3, issue.5, pp.714-723, 2006.
DOI : 10.1002/path.1924

W. Choi, D. Weisenburger, and T. Greiner, A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy, Clinical Cancer Research, vol.15, issue.17, pp.5494-5502, 2009.
DOI : 10.1158/1078-0432.CCR-09-0113

H. Nyman, M. Adde, and M. Karjalainen-lindsberg, Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy, Blood, vol.109, issue.11, pp.4930-4935, 2007.
DOI : 10.1182/blood-2006-09-047068

Y. Natkunam, P. Farinha, and E. Hsi, LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab, Journal of Clinical Oncology, vol.26, issue.3, pp.447-454, 2008.
DOI : 10.1200/JCO.2007.13.0690

P. Meyer, K. Fu, and T. Greiner, Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab, Journal of Clinical Oncology, vol.29, issue.2, pp.200-207, 2011.
DOI : 10.1200/JCO.2010.30.0368

C. Visco, Y. Li, and Z. Xu-monette, Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study, Leukemia, vol.84, issue.9, pp.2103-2113, 2012.
DOI : 10.1016/j.immuni.2004.06.010

D. De-jong, A. Rosenwald, and M. Chhanabhai, Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications???A Study From the Lunenburg Lymphoma Biomarker Consortium, Journal of Clinical Oncology, vol.25, issue.7, pp.805-812, 2007.
DOI : 10.1200/JCO.2006.09.4490

R. Coutinho, A. Clear, and A. Owen, Poor Concordance among Nine Immunohistochemistry Classifiers of Cell-of-Origin for Diffuse Large B-Cell Lymphoma: Implications for Therapeutic Strategies, Clinical Cancer Research, vol.19, issue.24, pp.6686-6695, 2013.
DOI : 10.1158/1078-0432.CCR-13-1482

G. Gutiérrez-garcía, T. Cardesa-salzmann, and F. Climent, Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy, Blood, vol.117, issue.18, pp.4836-4843, 2011.
DOI : 10.1182/blood-2010-12-322362

G. Ott, M. Ziepert, and W. Klapper, Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL, Blood, vol.116, issue.23, pp.4916-4925, 2010.
DOI : 10.1182/blood-2010-03-276766

J. Read, J. Koff, and L. Nastoupil, Evaluating Cell-of-Origin Subtype Methods for Predicting Diffuse Large B-Cell Lymphoma Survival: A Meta-Analysis of Gene Expression Profiling and Immunohistochemistry Algorithms, Clinical Lymphoma Myeloma and Leukemia, vol.14, issue.6, pp.460-467, 2014.
DOI : 10.1016/j.clml.2014.05.002

S. Barrans, S. Crouch, and M. Care, Whole genome expression profiling based on paraffin embedded tissue can be used to classify diffuse large B-cell lymphoma and predict clinical outcome, British Journal of Haematology, vol.100, issue.Suppl. 1, pp.441-453, 2012.
DOI : 10.1111/bjh.12045

P. Williams, R. Li, and N. Johnson, A Novel Method of Amplification of FFPET-Derived RNA Enables Accurate Disease Classification with Microarrays, The Journal of Molecular Diagnostics, vol.12, issue.5, pp.680-686, 2010.
DOI : 10.2353/jmoldx.2010.090164

A. Collie, J. Nölling, and K. Divakar, system, British Journal of Haematology, vol.110, issue.2, pp.281-285, 2014.
DOI : 10.1111/bjh.12983

N. Masqué-soler, M. Szczepanowski, and C. Kohler, Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens, Blood, vol.122, issue.11, pp.1985-1986, 2013.
DOI : 10.1182/blood-2013-06-508937

R. Roberts, C. Sabalos, and M. Leblanc, Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma, Laboratory Investigation, vol.33, issue.10, pp.979-997, 2007.
DOI : 10.1038/labinvest.3700665

D. Scott, G. Wright, and P. Williams, Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue, Blood, vol.123, issue.8, pp.1214-1217, 2014.
DOI : 10.1182/blood-2013-11-536433

M. Veldman-jones, Z. Lai, and M. Wappett, Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System, Clinical Cancer Research, vol.21, issue.10, pp.2367-2378, 2015.
DOI : 10.1158/1078-0432.CCR-14-0357

X. Xue, N. Zeng, Z. Gao, and M. Du, Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR, Laboratory Investigation, vol.110, issue.1, pp.113-120, 2015.
DOI : 10.1038/labinvest.2014.136
URL : https://www.repository.cam.ac.uk/bitstream/1810/247037/1/Xue%20et%20al%202015%20Laboratory%20Investigation.pdf

D. Scott, A. Mottok, and D. Ennishi, Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies, Journal of Clinical Oncology, vol.33, issue.26, pp.2848-2856, 2015.
DOI : 10.1200/JCO.2014.60.2383

D. Scott, Cell-of-Origin in Diffuse Large B-Cell Lymphoma: Are the Assays Ready for the Clinic?, American Society of Clinical Oncology Educational Book, vol.35, pp.458-466, 2015.
DOI : 10.14694/EdBook_AM.2015.35.e458

S. Galimberti, S. Luminari, and E. Ciabatti, Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial, Clinical Cancer Research, vol.20, issue.24, pp.6398-6405, 2014.
DOI : 10.1158/1078-0432.CCR-14-0407

C. Pott, E. Hoster, and M. Delfau-larue, Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study, Blood, vol.115, issue.16, pp.3215-3223, 2010.
DOI : 10.1182/blood-2009-06-230250
URL : https://hal.archives-ouvertes.fr/hal-00476460

S. Böttcher, M. Ritgen, and K. Fischer, Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial, Journal of Clinical Oncology, vol.30, issue.9, pp.980-988, 2012.
DOI : 10.1200/JCO.2011.36.9348

M. Ladetto, C. Lobetti-bodoni, and B. Mantoan, Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program, Blood, vol.122, issue.23, pp.3759-3766, 2013.
DOI : 10.1182/blood-2013-06-507319

C. Lobetti-bodoni, B. Mantoan, and L. Monitillo, Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma, Therapeutic Advances in Hematology, vol.11, issue.3, pp.189-198, 2013.
DOI : 10.1177/2040620713480522

H. Liu, J. Johnson, and G. Koval, Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909, Haematologica, vol.97, issue.4, pp.579-585, 2012.
DOI : 10.3324/haematol.2011.050203

C. Pott, C. Schrader, and S. Gesk, Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma, Blood, vol.107, issue.6, pp.2271-2278, 2006.
DOI : 10.1182/blood-2005-07-2845

M. Ladetto, D. Marco, F. Benedetti, and F. , Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage, Blood, vol.111, issue.8, pp.4004-4013, 2008.
DOI : 10.1182/blood-2007-10-116749

A. Rambaldi, E. Carlotti, and E. Oldani, Quantitative PCR of bone marrow BCL2/IgH+ cells at diagnosis predicts treatment response and long-term outcome in follicular non-Hodgkin lymphoma, Blood, vol.105, issue.9, pp.3428-3433, 2005.
DOI : 10.1182/blood-2004-06-2490

S. Böttcher, K. Fischer, and S. Stilgenbauer, Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab?a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial, Blood, vol.112, pp.125-126, 2008.

F. Bosch, A. Ferrer, and N. Villamor, Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication, Clinical Cancer Research, vol.14, issue.1, pp.155-161, 2008.
DOI : 10.1158/1078-0432.CCR-07-1371

A. Fink, S. Böttcher, and M. Ritgen, Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab, Leukemia, vol.27, issue.9, pp.1949-1952, 2013.
DOI : 10.1056/NEJM200012283432602

P. Hillmen, D. Cohen, and K. Cocks, A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia, British Journal of Haematology, vol.84, issue.5, pp.570-578, 2011.
DOI : 10.1111/j.1365-2141.2010.08317.x

C. Hirt, F. Schüler, and T. Kiefer, Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients, British Journal of Haematology, vol.88, issue.5, pp.631-640, 2008.
DOI : 10.1200/JCO.2004.07.170

M. Ladetto, P. Corradini, and S. Vallet, High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO), Blood, vol.100, issue.5, pp.1559-1565, 2002.
DOI : 10.1182/blood-2002-02-0621

P. Strati, M. Keating, O. Brien, and S. , Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL, Blood, vol.123, issue.24, pp.3727-3732, 2014.
DOI : 10.1182/blood-2013-11-538116

V. Goede, K. Fischer, and R. Busch, Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions, New England Journal of Medicine, vol.370, issue.12, pp.1101-1110, 2014.
DOI : 10.1056/NEJMoa1313984
URL : http://mediatum.ub.tum.de/doc/1244112/document.pdf

N. Andersen, L. Pedersen, and A. Laurell, Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma, Journal of Clinical Oncology, vol.27, issue.26, pp.4365-4370, 2009.
DOI : 10.1200/JCO.2008.21.3116

S. Ferrero, L. Monitillo, and B. Mantoan, Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma, Annals of Hematology, vol.377, issue.11, pp.1503-1511, 2013.
DOI : 10.1007/s00277-013-1797-y

M. Ritgen, S. Böttcher, and S. Stilgenbauer, Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial, Leukemia, vol.100, issue.7, pp.1377-1386, 2008.
DOI : 10.1016/j.bbmt.2006.06.004

;. Germany, M. Md, I. Klinik, K. Der-universität-münchen, /. Lmu et al., PF, Department of Haematology, Guys and St Thomas' and King's College Hospitals, appendix ESMO Lymphoma Consensus Conference Panel Members CB

M. , D. Of-hematology, . Rigshospitalet, . Copenhagen, . Denmark et al., IRCCS Reggio Emilia, and Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Innere Medizin I